Interferon alfa-2a in recurrent metastatic hemangiopericytoma
✍ Scribed by Lackner, Herwig ;Urban, Christian ;Dornbusch, Hans J�rgen ;Schwinger, Wolfgang ;Kerbl, Reinhold ;Sovinz, Petra
- Publisher
- John Wiley and Sons
- Year
- 2003
- Tongue
- English
- Weight
- 141 KB
- Volume
- 40
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Thirty-three patients with measurable metastatic renal cell carcinoma were entered into 2 consecutive phase II protocols using interferon alfa-2a. In protocol I, 20 patients were treated with interferon alfa-2a at a dose of 36 x I06 IU i.m. t.i.w. Vinblastine was also given t o 18 of these patients
Twenty-six patients with histologically proven metastatic malignant melanoma were included in a phase II trial of interferon alfa-2b (Intron A; Schering-Plough). Patients were given 10 X 10(6) IU/m2 of interferon alfa-2b subcutaneously three times a week until major intolerance or progression of dis
A Phase I study of interferon alfa-2a was conducted in 20 patients with disseminated cancer to establish the relationship between dose and interferon-related side effects. Fever was the most common side effect, and was not doserelated. Other side effects not related to dose included flu-like symptom